Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia

Strauss, Gregory P.; Sandt, Arthur R.; Catalano, Lauren T.; Allen, Daniel N.

doi:10.1016/j.comppsych.2012.05.009

Cited by 93 publications

(70 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the one hand, this is the first study, as far as we know, showing the relationship between EWB and thalamic-insular connectivity. This observation is in line with previous studies reporting the role of insula in EWB (Lewis et al 2013), and a stronger thalamus-insular structural and functional connectivity at rest in individuals with schizophrenia (Corradi-Dell'Acqua et al, 2012;Klingner et al, 2013), who report lower EWB than healthy individuals (Strauss, Sandt, Catalano, & Allen, 2012). On the other hand, this result suggests that the thalami-insular connectivity may be an important neural mechanism underlying neuroticism.…”

Section: Discussionsupporting

confidence: 77%

Different neural pathways linking personality traits and eudaimonic well-being: a resting-state functional magnetic resonance imaging study

Kong

Liu

Wang

et al. 2014

Cogn Affect Behav Neurosci

View full text Add to dashboard Cite

Eudaimonic well-being (EWB) is the fulfillment of human potential and a meaningful life. Previous studies have shown that personality traits, especially extraversion, neuroticism, and conscientiousness, significantly contribute to EWB. However, the neurobiological pathways linking personality and EWB are not understood. Here, we used restingstate functional magnetic resonance imaging (rs-fMRI) to investigate this issue. Specifically, we correlated individuals' EWB scores with the regional fractional amplitude of lowfrequency fluctuations (fALFF) of the brain, and then examined how personality traits predicted EWB-related spontaneous brain activity. We found that EWB was positively correlated with the fALFF in the right posterior superior temporal gyrus (pSTG) and thalamus, and negatively correlated with the strength of the thalamic-insular connectivity. More importantly, we found that personality traits influenced EWB in different ways. At the regional level, the fALFF in the pSTG and thalamus mediated the effects of neuroticism and extraversion on EWB, whereas the thalamus mediated the effect of conscientiousness on EWB. At the functional connectivity level, the thalamic-insular connectivity only mediated the effect of neuroticism on EWB. Taken together, our study provides the first evidence that EWB is associated with personality traits through different neural substrates.

show abstract

Section: Discussionsupporting

confidence: 77%

Different neural pathways linking personality traits and eudaimonic well-being: a resting-state functional magnetic resonance imaging study

Kong

Liu

Wang

et al. 2014

Cogn Affect Behav Neurosci

View full text Add to dashboard Cite

show abstract

“…However, according to our study results, the depression rate of schizophrenia patients living with their families was quite low, which indicates that family support and environmental conditions may be important factors in the manifestation of depression in these patients. This observation supports the importance of the family playing a role in psychosocial therapies for schizophrenia patients, as has been emphasized and elaborated recently (12)(13)(14)(15)(16).…”

Section: Discussionsupporting

confidence: 54%

“…For the treatment of schizophrenia symptoms and particularly of depression, the availability of familiar and social support is an important factor (12). It has been shown recently that therapeutic models for schizophrenia excluding the family are ineffective and insufficient (13,14).…”

Section: Introductionmentioning

confidence: 99%

Bakımevinde kalan şizofreni hastalarında yaşam kalitesi ve depresyon

Ertekin¹,

Er²,

Özayhan³

et al. 2015

Dusunen Adam

View full text Add to dashboard Cite

Quality of life and depression in schizophrenia patients living in a nursing homeObjective: Nursing homes are seen as alternative housing for patients with schizophrenia. However, it has not yet been established how suitable this accommodation is for schizophrenia patients. First aim of this study is to assess the quality of life and depression level in schizophrenic patients and compare this data with that of patients living with their families. Second aim is to assess factors related to the quality of living and depression state in all participants of this study. Method: This is a cross-sectional study conducted with patients presenting to the Psychotic Disorders Policlinic of the Beyhekim Psychiatric Clinic of Konya Training and Research Hospital consecutively between December 2012 and May 2013 who had received a diagnosis of schizophrenia according to DSM IV-TR. All participants were administered a sociodemographic data form, Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), and Quality of Life Scale for Schizophrenia Patients (QLSSP). Results: CDSS scores were found to be significantly increased in schizophrenic patients living in nursing homes. Their QLSSP scores, including interpersonal relations, occupational role, mental symptoms, personal belongings/activity scores, and total scores were statistically significantly low. A significant negative correlation was observed between negative symptom levels and occupational area, mental findings, and the personal belongings/activity areas of quality of life. Between positive symptom levels and quality of life, only scores in the occupational area showed a significant negative correlation. A significant negative correlation between CSDS and QLS was observed in all areas. Conclusion: Quality of life and depression need to be evaluated in all schizophrenia patients, as they are conditions that significantly affect treatment and prognosis. Keywords: Depression, quality of life, schizophrenia ÖZET Bakımevinde kalan şizofreni hastalarında yaşam kalitesi ve depresyonAmaç: Bakımevleri şizofreni hastaları için alternatif yaşam alanları olarak görülmektedir. Ancak bu tür yerlerin şizofreni hastaları için ne kadar uygun olduğu sorusu henüz cevaplandırılmamıştır. Bu çalışmanın birinci amacı bakımevlerinde yaşayan şizofreni hastalarının yaşam kalitesini ve depresyon düzeylerini değerlendirmek ve ailesiyle yaşayan hastalarla karşılaştırmaktı. İkinci amacı ise çalışmaya alınan tüm hastaların yaşam kalitesi ve depresyon durumlarıyla ilişkili faktörlerin değerlendirilmesiydi. Yöntem: Bu çalışma Aralık 2012-Mayıs 2013 tarihleri arasında Konya Eğitim ve Araştırma Hastanesi, Beyhekim Psikiyatri Kliniği, Psikotik Bozukluklar Polikliniğine ardışık olarak başvuran DSM-IV-TR'ye göre şizofreni tanısı alan hastaların katıldığı kesitsel bir çalışmadır. Tüm katılımcılara sosyodemografik veri formu, Kısa Psikiyatrik Değerlendirme Olçeği (KPDÖ), Pozitif ve Negatif Sendrom Ölçeği (PNSÖ), Calgary Şi...

show abstract

“…This finding is consistent with two recent studies suggesting that depression may be a predictor of well-being throughout the course of schizophrenia. 29,30 Further, improvement in depressive symptoms showed a significant correlation with improvement on subjective QOL. This is in line with previous observations that depression is associated with QOL in first-episode schizophrenia.…”

Section: Effect Of Blonanserin On Subjective Well-being and Qolmentioning

confidence: 93%

Retracted: Long‐term efficacy and safety of blonanserin in patients with first‐episode schizophrenia: A 1‐year open‐label trial

Ninomiya

Miyamoto

Tenjin

et al. 2014

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aims:The purpose of this study was to evaluate the long-term effectiveness and safety of blonanserin, a second-generation antipsychotic drug developed in Japan, in patients with first-episode schizophrenia.Methods: Twenty-three antipsychotic-naïve patients with first-episode schizophrenia were treated within an open-label, 1-year, prospective trial of blonanserin (2-24 mg/day). Clinical evaluations were conducted at baseline and 2, 6, and 12 months after the start of treatment. The main outcome measures were changes in subjective well-being and subjective quality of life, as assessed by the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version and the Schizophrenia Quality of Life Scale-Japanese version, respectively. Secondary outcome measures included the Positive and Negative Syndrome Scale, the Brief Assessment of Cognition in SchizophreniaJapanese version, laboratory tests, bodyweight, and extrapyramidal symptoms.Results: Fourteen patients (60.9%) remained on the study at 1 year. In the intention-to-treat analysis, significant improvements were observed in several subscales on the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version, the Schizophrenia Quality of Life Scale-Japanese version, and the Brief Assessment of Cognition in Schizophrenia-Japanese version, and in all factor scores on the Positive and Negative Syndrome Scale. Improvement in depressive symptoms with blonanserin treatment was positively correlated with improvements in subjective well-being and subjective quality of life, as well as verbal memory. No significant changes were noted for any safety measure during the 1-year study period. Conclusions:Blonanserin was well tolerated and effective for the treatment of first-episode schizophrenia in terms of subjective wellness, cognition, and a wide range of pathological symptoms. Further largescale studies are warranted to confirm our findings.Key words: blonanserin, cognition, first-episode schizophrenia, second-generation antipsychotics, subjective well-being. SCHIZOPHRENIA IS A chronic and debilitating disorder characterized by positive, negative, cognitive, and affective symptoms. Second-generation antipsychotics (SGA), excluding clozapine, are currently recommended in many guidelines as firstline agents for acute and maintenance therapy for schizophrenia. In four randomized, short-term, double-blind trials in patients with chronic schizophrenia, 3-6 blonanserin was shown to be as effective as haloperidol and risperidone in improving positive symptoms, and superior to haloperidol in improving negative symptoms. The overall safety profile of blonanserin Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. Email: y2ninomiya@marianna-u.ac.jp Received 25 December 2013; revised 19 April 2014; accepted 11 May 2014. R e t r a c t e dhas been similar to that of haloperidol and risperidone, 3,4,6,7 but blonanserin has been associated with a lower incidence of extrapyramidal symptoms (EPS) than haloperidol. 3,8...

show abstract

Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia

Cited by 93 publications

References 51 publications

Different neural pathways linking personality traits and eudaimonic well-being: a resting-state functional magnetic resonance imaging study

Different neural pathways linking personality traits and eudaimonic well-being: a resting-state functional magnetic resonance imaging study

Bakımevinde kalan şizofreni hastalarında yaşam kalitesi ve depresyon

Retracted: Long‐term efficacy and safety of blonanserin in patients with first‐episode schizophrenia: A 1‐year open‐label trial

Contact Info

Product

Resources

About